What's Left In $400M Skinny Label Row? A Lot, Court Says
By Theresa Schliep · December 13, 2024, 5:50 PM EST
A number of key issues remain live in the $400 million fight between Teva Pharmaceuticals and GlaxoSmithKline over whether the generic-drug maker induced healthcare providers to infringe the brand-name company's heart...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login